Question explored with the scientific record
If covid was so bad, why was the only recommendation from Drs to go to bed and take paracetamol?
The short version: the advice to rest and take paracetamol was the default because no drug had been proven to work for early COVID-19, and the evidence that did exist was weak, observational, and often contradicted.
In the first months of the pandemic, doctors had nothing solid to offer outpatients. The few early studies that claimed benefit for hydroxychloroquine plus azithromycin were small, non-randomized, and later contradicted by larger randomized trials that found no benefit [2, 8]. One commentary on the early evidence called it "weak at best" and pointed out that the most-cited French study had an odds ratio of 52 but a real risk ratio of about 5 — a massive inflation from a common-outcome bias [8]. By the time randomized controlled trials were done, the drug showed no effect on clinical status at 15 days [8]. So the "go to bed" advice was not a conspiracy; it was honest ignorance. The system had no early treatment to offer because the treatments that were proposed failed when tested properly.
What was not said is that the system also had no incentive to find cheap, unpatentable early treatments. The evidence that does exist for early intervention is almost entirely observational and industry-funded for later-stage drugs like remdesivir, which in one 2025 study of high-risk hospitalized patients showed no significant difference in mortality or oxygen need compared to control [16]. The burden of proof was never met for any early outpatient drug. The advice to rest and take paracetamol was the honest default of a system that had nothing better to offer — and that had not bothered to run the trials that might have found something.
My call: the advice was consistent with the evidence available at the time, which was thin and conflicted. Confidence: high that no proven early treatment existed; low that the system tried hard to find one.
Sources examined 32
-
Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study
A nationwide US prospective study found that receipt of the BNT162b2 BA.4/5 bivalent COVID-19 vaccine was associated with about a 40% lower risk and reduced burden of long COVID symptoms over six months among symptomatic adults with SARS-CoV-2 infection, compared with those not …
DOI: 10.3390/vaccines12020183 -
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
This review argues that hydroxychloroquine plus azithromycin or doxycycline, preferably with zinc, is safe and effective as early outpatient treatment for high-risk COVID-19 patients, citing non-randomized and observational evidence to prevent hospitalization.
DOI: 10.1093/aje/kwaa093 -
Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients
Vaccination with BNT162b2 is associated with reduced COVID-19–related declines in health-related quality of life and work productivity and with faster recovery among mildly symptomatic US outpatient adults during Omicron circulation.
DOI: 10.1186/s41687-022-00528-w -
Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study
Outpatients with acute COVID-19 follow a pattern of symptom progression from systemic and upper respiratory symptoms to lower respiratory and gastrointestinal symptoms, with initial symptom severity strongly predicting how long symptoms last and persistent symptoms being common.
DOI: 10.1136/bmjopen-2020-044154 -
INTERLEUKIN 6, AN IMPORTANT BIOMARKER OF CYTOKINE STORM IN COVID-19
Elevated interleukin-6 (IL-6) is linked to cytokine storm in COVID-19, suggesting that early IL-6 detection and repeated monitoring can help identify patients at risk of deterioration and guide targeted therapy.
DOI: 10.32553/ijmbs.v5i4.1894 -
Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies
We developed and validated the Symptoms Evolution of COVID-19 (SE-C19), a patient-reported electronic daily diary for outpatients, demonstrating content validity through interviews with 30 COVID-19 outpatients and five clinicians, and outlining plans for further psychometric eva…
DOI: 10.1186/s41687-022-00448-9 -
Development of a predictive prognostic rule for early assessment of COVID-19 patients in primary care settings
A population-based retrospective cohort study in Tarragona, Spain, developing and validating two simple prognostic rules (CD65-M and CD65RD-WMA) to predict ICU admission or death among community-dwelling adults aged 50 and older with COVID-19, using early clinical data to aid pr…
DOI: 10.1016/j.aprim.2021.102118 -
Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19
This commentary critiques Dr. Risch's opinion piece on hydroxychloroquine plus azithromycin for early outpatient COVID-19, highlighting factual errors, weak studies, confounding, and subsequent RCTs showing no benefit.
DOI: 10.1093/aje/kwaa189 -
Interrupted Time-Series Analysis to Evaluate the Impact of a Behavioral Change Outpatient Antibiotic Stewardship Intervention
Collection of conference abstracts evaluating antimicrobial stewardship robustness in Colorado hospitals and related interventions, showing high overall CDC core-element adherence but notable gaps under stricter criteria and in pediatrics, and demonstrating a large reduction in …
DOI: 10.1017/ash.2021.28 -
Outpatient management of kidney transplant recipients with suspected COVID‐19—Single‐center experience during the New York City surge
A single-center retrospective study describing the outpatient monitoring of 44 kidney transplant recipients with suspected COVID-19 in New York City during March–April 2020, showing extensive progression to hospitalization and highlighting the inadequacy of symptom-based outpati…
DOI: 10.1111/tid.13383 -
Diagnostic performance of upper airway sampling sites for SARS-CoV-2 and influenza testing
This randomized outpatient clinical trial in Copenhagen compares nasopharyngeal, throat, nasal, and saliva sampling for SARS-CoV-2 and influenza testing, finding throat swabs most sensitive for both viruses, saliva least effective for influenza, and a throat-plus-nasal combinati…
DOI: 10.1128/spectrum.02212-25 -
A A Multicentre ICET-A Study of Confirmed SARS-CoV-2 Infection in Patients with Hemoglobinopathies: Preliminary Data from 10 Countries
A retrospective multicenter ICET-A survey across 17 centers in 10 countries assessed epidemiology, clinical features, laboratory/radiologic findings, and outcomes of COVID-19 in 9,499 patients with hemoglobinopathies, identifying 13 confirmed cases with predominantly mild to mod…
DOI: 10.4084/mjhid.2020.046 -
Variants of the post-COVID syndrome course depending on age, gender, comorbidity and severity of COVID-19
Post-COVID syndrome variants vary by age, gender, comorbidity, and initial COVID-19 severity, with hospitalized patients showing more respiratory symptoms and higher cardiometabolic comorbidity than outpatients.
DOI: 10.32902/2663-0338-2023-1-14-19 -
The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
This retrospective study compares epidemiological characteristics of laboratory-confirmed and clinically diagnosed COVID-19 cases in Wuhan during the early epidemic, finding similar demographics and spatiotemporal patterns but higher severity and case-fatality in confirmed cases…
DOI: 10.1186/s41256-021-00200-8 -
Coronavirus disease 2019 (COVID-19) in neurology and neurosurgery: A scoping review of the early literature
This scoping review evaluates the early literature on COVID-19's impact on neurology and neurosurgery, highlighting neurological symptoms, potential neuroinvasive mechanisms of SARS-CoV-2, and changes in clinical practice during the pandemic.
DOI: 10.1016/j.clineuro.2020.105866 -
Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave
This study investigates the clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave, finding no significant difference in all-cause mortality or need for oxygen supplementation compared to a control g…
DOI: 10.1186/s12879-025-10585-3 -
Funding Sources of Therapeutic and Vaccine Clinical Trials for COVID-19 vs Non–COVID-19 Indications, 2020-2021
Public funding dominated the early COVID-19 therapeutic and vaccine clinical trials (Jan 2020–Aug 2021), with public institutions and public-private partnerships leading development and raising concerns about affordability and global access.
DOI: 10.1001/jamanetworkopen.2022.26892 -
Unveiling the clinical profiles of critically ill COVID-19 patients: insights from Ezhou during the early spread
A retrospective, single-center analysis of 98 critically ill COVID-19 patients in Ezhou during the early outbreak, detailing clinical characteristics, imaging findings, treatments, and a high 28-day mortality driven by older age and higher incidence of ARDS/MODS, with CT pattern…
DOI: 10.7717/peerj.20318 -
Drug repurposing in the treatment of COVID-19: A review
A comprehensive review summarizing drug repurposing efforts for COVID-19, detailing proposed mechanisms, early clinical and in vitro evidence, dosing considerations, and safety concerns across multiple antiviral and immunomodulatory agents.
DOI: 10.25081/rip.2021.v11.6611 -
Quick Sequential Organ Failure Assessment to identify clinical deterioration in adults with COVID-19: a retrospective cohort
This retrospective cohort study evaluates the performance of the quick Sequential Organ Failure Assessment (qSOFA) in identifying clinical deterioration in 813 adults with COVID-19, finding that while qSOFA has high specificity, it exhibits low sensitivity for detecting deterior…
DOI: 10.1590/1518-8345.7239.4530 -
Vaccines and drugs under clinical trials for prevention and treatment of COVID-19
A narrative review surveying the landscape of COVID-19 vaccines and therapeutics in clinical trials as of early 2021, summarizing candidate mechanisms, trial designs, and regulatory status along with early results and ongoing challenges.
DOI: 10.1007/s13337-020-00650-7 -
Using Tokenization and Random Forest Models to Predict Pandemic Trial Outcomes
This study develops a predictive model using tokenization and random forest techniques to identify COVID-19 clinical trials at risk of early cessation based on trial characteristics and metadata.
DOI: 10.22161/ijaems.112.18 -
Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics
A comprehensive narrative review of mesenchymal stem cell immunomodulation and regeneration as a potential therapeutic approach for COVID-19, synthesizing mechanistic insights, preclinical evidence, and early clinical trial data to discuss safety, feasibility, and future directi…
DOI: 10.1016/j.lfs.2020.118588 -
Potential Predictors of the Outcome of Tocilizumab Treatment in Patients with COVID-19-Associated Hyperinflammation
A retrospective cohort study identifying early clinical and laboratory predictors of response to tocilizumab in COVID-19-associated hyperinflammation (HIC), showing that dynamic changes in inflammatory biomarkers and the HIC score during days 1–5 after treatment differentiate su…
DOI: 10.36519/idcm.2025.475 -
Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
In a large longitudinal COVID-19 cohort, the authors integrated clinical, laboratory, and detailed immunological data to delineate distinct early and late disease patterns, identify immune- and organ-dysregulation signatures, and develop the COST risk score that robustly predict…
DOI: 10.1016/j.isci.2021.102752 -
Length of Disease More than Therapy Impacts Anxiety and Depression in Multiple Sclerosis
Shorter disease duration and female sex predict higher anxiety among people with multiple sclerosis during COVID-19, while disease-modifying therapies generally have little impact on anxiety or depression.
DOI: 10.33425/2692-7918.1043 -
COVID-19 Vaccine Boosters in People With Multiple Sclerosis
A multicenter, prospective study in people with multiple sclerosis on disease-modifying therapies shows that additional COVID-19 vaccine boosters broaden cross-variant Spike IgG and neutralizing antibody protection against emerging SARS-CoV-2 variants, with machine-learning mode…
DOI: 10.1212/nxi.0000000000200443 -
COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections
This study investigates the impact of disease-modifying therapies on the humoral response to COVID-19 vaccination in patients with multiple sclerosis and other neuroinflammatory disorders, revealing significant differences in seroconversion rates based on the type of therapy use…
DOI: 10.3390/vaccines10050695 -
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases
A multicenter, year-long prospective online study (MSReCOV) reports baseline results on the risk and impact of COVID-19 in people with neuroinflammatory diseases (primarily multiple sclerosis) compared with neurologically asymptomatic reference participants, finding similar rate…
DOI: 10.1002/acn3.51314 -
COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
A retrospective, multicentre Argentine case series describing 18 multiple sclerosis patients on teriflunomide who developed COVID-19; all had mild disease, did not discontinue teriflunomide, and fully recovered, supporting safety of continuing therapy during infection.
DOI: 10.1016/j.msard.2021.103049 -
Early Vitamin D Supplementation in Multiple Sclerosis: A Crucial Preventive Approach in 2025
This is a narrative review advocating early, proactive vitamin D (calcitriol/25(OH)D) supplementation in people with multiple sclerosis (including pediatric-onset and prodromal contexts) to modulate immune dysregulation, seal the blood–brain barrier, potentially mitigate Epstein…
DOI: 10.64585/3065-0097-2-1-15 -
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort
This study investigates the dynamics of SARS-CoV-2 infections and vaccinations in a large cohort of people with multiple sclerosis (pwMS) in Germany, revealing significant associations between demographic and disease-related factors and vaccination/infection rates.
DOI: 10.3390/vaccines12030265